Saletu B, Anderer P, Saletu-Zyhlarz G M, Pascual-Marqui R D
Department of Psychiatry, University of Vienna, Vienna, Austria.
Methods Find Exp Clin Pharmacol. 2002;24 Suppl D:97-106.
Clinically well-defined diagnostic subgroups of mental disorders, such as schizophrenia with predominantly plus and minus symptomatology, major depression, generalized anxiety disorder, agoraphobia, obsessive-compulsive disorder, multiinfarct dementia, senile dementia of the Alzheimer type and alcohol dependence, show electroencephalogram (EEG) maps that differ statistically both from each other and from normal controls. Representative drugs of the main psychopharmacological classes, such as sedative and nonsedative neuroleptics and antidepressants, tranquilizers, hypnotics, psychostimulants and cognition-enhancing drugs, induce significant and typical changes to normal human brain function compared with placebo, in which many variables are opposite to the above-mentioned differences between psychiatric patients and normal controls. Thus, by considering these differences between psychotropic drugs and placebo in normal subjects, as well as between mental disorder patients and normal controls, it may be possible to choose the optimum drug for a specific patient according to a key-lock principle, since the drug should normalize the deviant brain function. This is supported by low-resolution brain electromagnetic tomography (LORETA), which identifies brain regions affected by psychiatric disorders and psychotropic drugs.
